ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

TAVR (TAVI)

January 4, 2019
Edwards Lifesciences announced that the SAPIEN 3 Ultra system has received US Food and Drug Administration approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are determined to be at intermediate or greater risk of open-heart surgery.
December 18, 2018
The authors, using the STS/ACC TVT Registry, analyzed the the occurrence of patient-prosthesis mismatch (PPM) in 62,215 patients enrolled between 2014 and 2017. They found that severe and moderate PPM occurred in 12% and 25% of patients, respectively.
December 18, 2018
This study analyzed the cost-effectiveness of TAVR versus SAVR in 3110 intermediate-risk aortic stenosis patients from the PARTNER-2 trial. Using a Markov model, the authors found that TAVR is economically dominant from the perspective of lifetime cost-effectiveness in the US healthcare system.
December 14, 2018
Patient Care and General Interest Truly remote percutaneous coronary intervention was performed in five human patients at Apex Heart Institute in Ahmedabad, India.
November 27, 2018
Hebeler and colleagues hypothesized that the inclusion of measures of frailty might improve the prediction of mortality one-year after transcatheter aortic valve replacement (TAVR).
November 19, 2018
Conzelmann and colleagues aimed to gain information about outcomes of transcatheter aortic valve replacement (TAVR) procedures in patients with coronary heights less than 7 mm. These procedures are not common, as one of the contraindications for TAVR is a low coronary height.
November 7, 2018
The authors of this study analyzed neurological events and quality-of-life in the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial.  A total of 1746 patients with aortic stenosis and intermediate surgical risk were randomized to either TAVI or SAVR.
October 25, 2018
Olaf Wendler of King's College Hospital in London, UK, presents a discussion on the 2017 ESC/EACTS guidelines for the management of valvular heart disease.
October 17, 2018
Find it here: the 32nd EACTS Annual Meeting in Milan, Italy

Pages